![Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial - The Lancet Gastroenterology & Hepatology Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial - The Lancet Gastroenterology & Hepatology](https://www.thelancet.com/cms/attachment/418fc973-9e86-48ff-98dc-4d4d2addb9b0/gr2.gif)
Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial - The Lancet Gastroenterology & Hepatology
![An overview of short bowel syndrome management: adherence, adaptation, and practical recommendations. | Semantic Scholar An overview of short bowel syndrome management: adherence, adaptation, and practical recommendations. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c8c9bb3279f15cebf142468febe6c7ae3433212d/6-Figure2-1.png)
An overview of short bowel syndrome management: adherence, adaptation, and practical recommendations. | Semantic Scholar
![Serostim ® Treatment of Short Bowel Syndrome NDA Division of Gastrointestinal and Coagulation Drug Products Hugo E. Gallo-Torres, M.D., Ph.D, PNS. - ppt download Serostim ® Treatment of Short Bowel Syndrome NDA Division of Gastrointestinal and Coagulation Drug Products Hugo E. Gallo-Torres, M.D., Ph.D, PNS. - ppt download](https://images.slideplayer.com/25/8050056/slides/slide_4.jpg)